Canopy Growth (CGC) Projected to Post Earnings on Friday

Canopy Growth (NASDAQ:CGC) is expected to release its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect Canopy Growth to post earnings of ($0.03) per share and revenue of $70.9570 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Friday, February 6, 2026 at 10:00 AM ET.

Canopy Growth (NASDAQ:CGC) last announced its earnings results on Friday, November 7th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.10. The business had revenue of $47.86 million for the quarter, compared to the consensus estimate of $71.82 million. Canopy Growth had a negative return on equity of 61.97% and a negative net margin of 113.21%. On average, analysts expect Canopy Growth to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Canopy Growth Stock Up 7.3%

NASDAQ CGC opened at $1.17 on Wednesday. The company has a quick ratio of 4.23, a current ratio of 5.50 and a debt-to-equity ratio of 0.31. Canopy Growth has a fifty-two week low of $0.77 and a fifty-two week high of $2.90. The business has a 50 day moving average price of $1.25 and a two-hundred day moving average price of $1.29. The stock has a market cap of $431.10 million, a PE ratio of -0.60 and a beta of 0.56.

Institutional Trading of Canopy Growth

Several institutional investors and hedge funds have recently bought and sold shares of CGC. Boothbay Fund Management LLC acquired a new position in shares of Canopy Growth in the 2nd quarter worth approximately $30,000. Sender Co & Partners Inc. acquired a new position in Canopy Growth in the third quarter worth $63,000. Osaic Holdings Inc. increased its stake in Canopy Growth by 77.6% during the second quarter. Osaic Holdings Inc. now owns 75,335 shares of the company’s stock valued at $92,000 after purchasing an additional 32,927 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Canopy Growth by 111.3% during the third quarter. Bank of America Corp DE now owns 87,095 shares of the company’s stock worth $127,000 after purchasing an additional 45,871 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Canopy Growth by 35,753.8% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 100,032 shares of the company’s stock worth $146,000 after buying an additional 99,753 shares during the last quarter. Institutional investors and hedge funds own 3.33% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CGC shares. Benchmark raised shares of Canopy Growth from a “sell” rating to a “hold” rating in a report on Monday, November 10th. Wall Street Zen upgraded Canopy Growth from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Alliance Global Partners reiterated a “neutral” rating on shares of Canopy Growth in a research note on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Canopy Growth in a report on Wednesday, January 21st. Three analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce”.

About Canopy Growth

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.